Top Markets
Coin of the day
Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFI
株式のランク #40134
Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge,... Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
株価
$0.0039
最終同期: 2023-10-27
時価総額
$235.97K
変化(1日)
-13.33%
変化(1年)
0.00%
US
取引 Infinity Pharmaceuticals, Inc. (INFI)

カテゴリー

Infinity Pharmaceuticals, Inc.(INFI)のEPS
2026 時点のEPS TTM: 0
Infinity Pharmaceuticals, Inc.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
Infinity Pharmaceuticals, Inc.のEPS履歴(2026から2026まで)
各年末時点のEPS
EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS